Atopic Dermatitis/Atopic Eczema – Emerging Therapies – Dupixent Launch Tracking Wave 1 (US)

Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months after Dupixent’s launch from surveys of U.S. dermatologists. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial, adoption, and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What are U.S. dermatologists’ awareness of and familiarity with Dupixent, and what are their perceptions of the product?
  • For which patients are prescribers of Dupixent prescribing the product, what are their reasons for prescribing it, and how satisfied are they with it?
  • What promotional messages and activities are Sanofi and Regeneron using to support Dupixent’s launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with other recent product launches for AD?

Methodology: ~75-100 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Dupixent

Key companies: Sanofi/Regeneron

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Dupixent Launch Tracking Wave 1 (US)
    • Key Findings
      • Benchmarking Dupixent Launch Success vs. Other Launched Brands
        • Key Findings
        • Benchmarking Dupixentu2019s Launch Success vs. Other Launched Brands
      • Prescriber and Nonprescriber Profiles
        • Differences Between Dupixent Prescribers and Nonprescribers
        • Differences Between Dupixent Prescriber and Nonprescriber Profiles
      • Dupixent Awareness and Perceptions
        • Unaided and Aided Awareness of Dupixent
          • Unaided Awareness of Recently Approved Drugs for Atopic Dermatitis
          • Awareness of Dupixent
          • Awareness of Dupixent's Approval for AD
          • Awareness of the Administration of Dupixent
          • Estimated Cost of Dupixent
        • Familiarity with Dupixent
          • Sources of Familiarity with Dupixent
            • Initial Reaction to and Interest in Dupixent
              • Initial Reaction to Dupixent After Viewing Product Profile
              • Level of Interest in Dupixent
            • Impressions of Dupixent
              • Existence of Dupixent Attributes About Which Dermatologists Were Unaware
              • Aspects of Dupixent Profile of Which Dermatologists Were Unaware
              • Perceived Uniqueness of Dupixent
              • Perceived Value of Dupixent Attributes
              • Risk-Benefit Ratio of Dupixent
              • Unaided Advantages of Dupixent
              • Unaided Disadvantages of Dupixent
            • Prescriber and Nonprescriber Profiles
              • Differences Between Dupixent Prescriber and Nonprescriber Profiles
          • Dupixent Trial and Use
            • Willingness to Prescribe Dupixent
              • Willingness to Prescribe Dupixent to Patients
              • Impact of Attributes on Willingness to Prescribe Dupixent
              • Mean Impact of Attributes on Willingness to Prescribe Dupixent
            • Number of Patients Currently Receiving Dupixent
              • Agents Currently Prescribed to AD Patients
              • Dupixent Patient Volume
              • Timing of Dupixent Prescription
              • Dupixent Patients by Disease Severity
              • Origination of Patients Treated with Dupixent
              • Dupixent Discontinuation Rate
              • Agents to Which Patients Switched After Discontinuing Dupixent
              • Reasons for Discontinuing Dupixent
              • Agents from Which Patients Were Switched to Dupixent
              • Reasons for Switching to Dupixent from Previous Therapy
              • Agents to Which Dupixent Was Added
              • Reasons for Prescribing Dupixent
              • Number of Patient Inquiries for Dupixent
              • Result of Specific Patient Requests for Dupixent
            • Reasons for Not Yet Prescribing Dupixent
              • Anticipated Dupixent Use
                • Nonprescriber Timeline for Dupixent Trial
                • Candidates for Dupixent by AD Patient Population
                • Candidates for Dupixent by Treatment History
                • Therapies That Dupixent Is Likely to Replace
                • Obstacles to Prescribing Dupixent
                • Percentage of Patients Expected to Receive Prescription Drug Treatment for AD in Next Six Months
                • Agents That Dermatologists Expect to Prescribe to AD Patients in the Next Six Months
              • Dupixent's Performance on Key Attributes
                • Overall Satisfaction with Dupixent
                • Ease of Dupixent's Managed Care Approval Process
                • Requirements for Dupixent's Managed Care Approval
                • Mean Total Dupixent Performance on Key Attributes
                • Total Dupixent Performance on Key Attributes
                • Mean Dupixent Performance on Key Attributes: Prescribers vs. Nonprescribers
                • Dupixent Performance on Key Attributes: Prescribers vs. Nonprescribers
            • Effectiveness of Face-to-Face Detailing for Dupixent
              • Frequency and Reach of Dupixent's Sales Representatives
                • Most Recent Contact with a Dupixent Representative
                • Frequency of Dupixent Representatives' Visits to Surveyed Dermatologists
                • Samples Provided by Dupixent Representatives
                • Surveyed Dermatologists' Interest in Samples from Dupixent Representatives
              • Surveyed Dermatologists' Satisfaction with Sales Performance of Dupixent Representatives
                • Sales Performance of Dupixent Representatives
                • Mean Rating of Dupixent Representatives' Sales Performance
              • Surveyed Dermatologists' Recall of Dupixent Message
                • Message Recall During Recent Detail
                • Agents Positioned Against Dupixent During Representative Visit
                • Ideal Dupixent Candidate Suggested by Representative
                • Materials Used During Dupixent Representatives' Visit
            • Appendix
              • Primary Market Research
                • Patient Allocation by Age
                • Diagnosis Criteria for AD Severity

          launch Related Market Assessment Reports